RFK Jr. at HHS Just Wiped $25B Off Vaccine Stocks-Now the Real Selloff May Begin

The initial selloff reflected policy fear, not company-specific news

This was more than a routine dip. When reports about Trump's expected pick reached markets, investors appeared to be re-pricing vaccine-sector risk on the idea that leadership change at HHS could alter the policy environment.

According to reporting, the final half hour of trading was where the move became clearest: more than $25 billion was erased from major pharma market caps as word spread.

The hit was broad. Pfizer, GSK, Sanofi, Merck, Moderna, BioNTech, and Novavax all sold off, suggesting the market was reacting to sector-wide policy risk rather than company-specific developments. Sanofi alone lost over $5 billion in valuation. Moderna was hit hardest among the large caps at -11% since 3:30 p.m. and finished the day down more than 5%. Pfizer fell more than 2%, Merck dropped about 3.5%, Novavax slipped 8% since the report and more than 7% at the close, BioNTech ended more than 6% lower, GSK finished roughly 2% lower, and Bavarian Nordic fell 17% the following Friday. That kind of broad reaction is what traders usually look for when they think policy sentiment is shifting.

This matters because the mechanism does not require immediate legislation. HHS has oversight reach over major parts of the vaccine ecosystem, including the FDA and CDC, so skeptical messaging from the top can influence recommendations, procurement confidence, and public demand. We already have one example of how quickly those levers can move: when Kennedy demanded the agency stop running vaccine awareness campaigns, flu marketing was directly affected. That helps explain why vaccine stocks did not trade like a normal biotech basket. The market appears to be front-running a change in tone and authority rather than waiting for a final policy outcome.

How messaging at HHS can become revenue risk

Advisory changes and proposed schedule revisions

One trading day can pass quickly; damaged trust in the public-health apparatus can linger.

Kennedy has already dismissed members of the Advisory Committee on Immunization Practices and replaced them with people more critical of the vaccine status quo. He has also reduced the number of childhood vaccinations recommended by the federal government. Reuters reported that he pushed proposals including eliminating the entire federal immunization schedule for American children.

That matters because vaccine demand is partly behavioral. If the government stops endorsing shots, demand can soften before any law formally changes. In 2025, Kennedy demanded that the agency stop running vaccine awareness campaigns during what a CDC official described as an active flu season. For vaccine makers, that is not just an optics problem. It can mean fewer doses, weaker launch momentum, and tougher conversations with providers and parents.

Why public trust matters to valuation

Vaccine franchises have long been valued on the strength of recurring demand, recommended schedules, and public confidence. The importance of that trust is easy to see: childhood vaccines are projected to prevent up to 5 million deaths a year.

The current concern is that confidence itself is coming under pressure. Reporting has highlighted deep staffing churn at HHS, including nearly 20% of the department's staff have left, while more than 1,000 current and former HHS employees have called for Kennedy to resign. The CDC has also been shaken by the firing of Director Susan Monarez and the departure of several senior leaders.

Investors have every reason to wait for confirmation before assuming a specific policy outcome. But the market is not just reacting to one actor; it is reacting to someone with a history of spreading health information that scientists say is false. When that person is positioned to influence the institutions that support vaccine confidence, sentiment can move before financial statements do.

The near-term debate is timing: courts and process may slow the damage

Bulls have a credible procedural argument. A federal judge has already issued a temporary block of Kennedy's vaccine-policy changes, which shows the courts can slow implementation even if they do not stop the agenda entirely. The same applies to Washington: If his nomination is ratified by the Senate, the market has to price a confirmation fight, not just a smooth takeover.

Still, the bearish case remains stronger in the near term because markets often trade the expected path of hostility before policy is fully resolved. Even delayed action can keep uncertainty elevated and pressure valuation.

What could support a rebound

• Legal resistance may slow changes. A judge moving quickly to block parts of the agenda suggests the process does not have an open lane.
• Senate confirmation may create friction. Public-health opposition increases the odds of a contested process.
• Narrative heat can fade if major policy steps are delayed or diluted.

What could keep the pressure on

• Confirmation moves forward.
• Kennedy's team pursues more vaccine-policy changes.
• Leadership churn continues to weaken confidence in the system.

The trade from here depends on process, not momentum alone

This still looks like a high-volatility policy trade rather than a clean bottom-fishing setup.

Key catalysts to watch

• Watch the legal path first. A federal judge has already issued a temporary block of Kennedy's vaccine-policy changes. Faster blocks may help limit the selloff; slower rulings may leave pressure in place longer.
• Watch confirmation. If his nomination is ratified by the Senate, investors will have to price a longer runway for change and ongoing uncertainty.
• Watch internal morale. With nearly 20% of the department's staff have left and more than 1,000 current and former HHS employees calling for Kennedy to resign, execution risk is becoming harder to ignore.
• Watch where the narrative spreads. Kennedy's Take Back Your Health Tour and related state-and-local efforts show that this debate is not confined to Washington.

For now, the cautious read is still the cleaner one: stay tactical, watch the levers, and do not mistake headline chaos for a fully cleaned-out valuation.